Skip to main content
Premium Trial:

Request an Annual Quote

Paragon Genomics ParagonDesigner

Paragon Genomics has launched ParagonDesigner, a web-based tool that enables rapid design of CleanPlex Custom NGS Panels. The online portal features a streamlined, user-friendly interface that simplifies the assay design process, allowing researchers to build customized next-generation sequencing assays for their specific needs. The custom panels are powered by Paragon's CleanPlex technology, an ultra-high multiplexed PCR-based target enrichment chemistry that makes it possible to include a large number of genomic targets in a single assay.  With ParagonDesigner, users define the content of their custom NGS assays by submitting their targets online. ParagonDesigner features a database of more than 1,300 pre-designed, clinically-relevant human genes, allowing CleanPlex Custom NGS Panels to be instantly assembled for most applications. The design tool also issues a report on the estimated panel size and design coverage for review prior to submission. Custom NGS panels are delivered in two to four weeks, the company said.
The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.